On Sunday, May 18, 2025, from 6:30-7:30 PM PDT, join global experts Nicola Hanania, MD, MS, Lauren Cohn, MD, and Klaus Rabe, MD, PhD, for an educational symposium titled “Expanding Our Understanding of COPD: The Role of IL-33 in Chronic Airway Inflammation”. They will discuss the burden of COPD, the role of IL-33 in disease pathophysiology, and key insights from clinical trials.  The learning objectives of the symposium are to communicate the burden of COPD, including its impact on patients’ QoL and the unmet needs that persist​. Describe the role of IL-33 in the pathophysiology of COPD, including its contribution to inflammation, airway remodeling, and disease progression​. Understand the clinical trial data investigating the impact of targeting the IL-33 pathway in COPD.

The agenda topics are Understanding the Burden of COPD Across the Spectrum of Inflammatory Profiles, How Does IL-33 Influence COPD Pathogenesis? and Data Presentation: Exploring the IL-33 Pathway in COPD​.

This symposium will conclude with an interactive Q&A with our distinguished faculty, Nicola Hanania, MD, MS, Lauren Cohn, MD, and Klaus Rabe, MD, PhD. Please come ready with any questions you may have.

Registration for the 2025 ATS congress is required to attend the symposium live.

Asthma and COPD are chronic, heterogeneous, inflammatory diseases of the lower airway characterized by airflow obstruction, shortness of breath, and exacerbations, which are serious acute respiratory events marked by heightened respiratory symptoms. Despite advances in care, exacerbations remain a significant clinical challenge, contributing to lung function decline, frequent hospitalizations, reduced quality of life, and increased mortality. Therefore, it is important for healthcare professionals to recognize the shared inflammatory mechanisms and the distinct ways these diseases may present in clinical practice.